Press Releases.

Media Contact: Mingjie Xie, M.Sc., M.B.A., CEO, +1 (519) 593-2260, pr@rapidnovor.com

In The News.

July 28, 2020 – By Beth Gallagher, University of Waterloo
A world-leading University of Waterloo spinoff company, that decodes blood samples for potential treatments for illnesses like cancer and COVID-19, is expanding operations with the help of a $5-million USD investment.
Waterloo tech profiles antibodies in blood of COVID-19 patients

Aug 20, 2018 – By Maggie Lynch, Outsourcing-Pharma.com
Rapid Novor has expanded its proteomics lab with the addition of a third mass spectrometer – enabling the company to take on more projects, says CEO.
Rapid Novor expands proteomics lab with third mass spectrometer

Mar 23, 2018 – HiTechCanada – Interview conducted by Huayu Niu, HiTechCanada.
HiTech Face to Face (Language: Mandarin)

Jan 9, 2018 – News-Medical.Net – Insights from industry – An interview with Mingjie Xie, conducted by James Ives, MPsych
Deciphering Antibodies with Next-Generation Protein Sequencing Technology

Nov 15, 2017 – Ontario Genomics
Ontario Genomics has closed an investment in Rapid Novor, a Kitchener-Waterloo based biotech company that provides rapid, accurate, de novo protein sequencing services across Canada and internationally.
Ontario Genomics invests in antibody protein sequencing company Rapid Novor

Aug 21, 2017 – CEOCFO Magazine – Interview conducted by: Lynn Fosse, Senior Editor, CEOCFO Magazine, Published – August 21, 2017
CEOCFO Magazine Interviews Rapid Novor Inc CEO, Mingjie Xie

Jul 19, 2017 – Waterloo Region Record
Rapid Novor, a startup that went through the Accelerator Centre in the David Johnston Research and Technology Park, is now based at 44 Gaukel St. in downtown Kitchener. Specializing in what’s called protein sequencing, the six-member team is among a small, but growing, number of biotech startups in the region.
Big science out of a small lab

Talk to Our Scientists.

We Have Sequenced 4000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.

Talk to Our Scientists.

We Have Sequenced 3000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics

Talk to our scientists. We have sequenced over 4000 antibodies and we are eager to help you.